VISTIDE
LOE ApproachingNDAINTRAVENOUSSOLUTION
Approved
Jun 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VISTIDE is an intravenous small-molecule antiviral approved by the FDA in 1996 for treatment of cytomegalovirus (CMV) infections, particularly in immunocompromised patients. The drug mechanism involves nucleotide analog activity targeting viral DNA polymerase. It represents a legacy antiviral product from Gilead Sciences' early portfolio.
LOE Approaching
With LOE approaching and minimal linked job openings, the VISTIDE team is likely a small legacy franchise operating in wind-down mode with limited commercial growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VISTIDE offers minimal career advancement opportunities given zero linked job openings and the product's LOE-approaching status. Career growth on this legacy franchise is constrained by limited commercial investment and lack of clinical expansion activities.
Brand ManagerField Sales Representative
Worked on VISTIDE at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.